IDH1 and glioblastoma: Furthermore, both Forma Therapeutics’ FT2102 and Bayer’s BAY1436032 target IDH1 R132 tumors (R132X for BAY1436032), with trials actively enrolling patients across several tumor types, including GBM (NCT03684811 and NCT02746081) [162].